Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

In this MEDtalk, the ADAURA study is presented by Masahiro Tsuboi, a Thoracic surgeon in Japan. The study explores osimertinib as adjuvant therapy for patients with resected EGFR-mutated non-small-cell lung cancer and indicates osimertinib to be an effective adjuvant treatment for these patients.